Ted Yednock Purchases 30,646 Shares of ANNX

EVP & Chief Innovation Officer Ted Yednock buys ANNX shares for $56,695.

Written by Trueearnings · Published Jun 15, 2026, 5:04 PM EDT

Key Points

Ted Yednock, EVP & Chief Innovation Officer at ANNX, bought 30,646 shares at $1.85 each, totaling $56,695 on June 11, 2026.
Shares of ANNX were trading near $4.81 with institutional investors like Redmile Group and BlackRock showing significant interest.
Analysts from firms like Goldman Sachs and Chardan Capital have set price targets ranging from $7 to $27, with a mix of 'hold' and 'buy' ratings.

Ted Yednock, the Executive Vice President and Chief Innovation Officer at ANNX, made a notable purchase of company shares on June 11, 2026. Yednock acquired 30,646 shares at an average price of $1.85 each, amounting to a total investment of $56,695. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at ANNX

On June 11, 2026, several insiders at ANNX made significant stock acquisitions. Ted Yednock, EVP & Chief Innovation Officer, bought 30,646 shares at $1.85 each. Other insiders, including William Jr. Jones, Bettina Cockroft, Jung Choi, William Waddill, and William Carson, each acquired 65,000 shares without a disclosed price, indicating a concerted effort among the company's leadership to increase their stakes.

Other Institutional Activity in ANNX

Institutional investors have also shown interest in ANNX. Redmile Group, LLC increased its holdings by 4,499,124 shares, bringing its total to 14,549,768 shares valued at approximately $80.6 million. BlackRock, Inc. added 1,978,075 shares, ending with 10,938,509 shares worth about $60.6 million. FMR LLC also grew its position by 413,178 shares, reaching a total of 10,635,648 shares valued at $58.9 million. On the other hand, BVF Inc/IL trimmed its stake by 429,907 shares, leaving it with 8,698,173 shares valued at $48.2 million. Meanwhile, State Street Corp significantly boosted its holdings by 2,267,070 shares, totaling 6,919,255 shares valued at $38.3 million.

ANNX Stock Snapshot

Shares of ANNX were trading near $4.81 recently. The company has been attracting attention from various institutional investors, as evidenced by recent buying activity.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for ANNX. On May 12, 2026, Goldman Sachs initiated coverage with a 'hold' rating and a $7 price target. Earlier in the year, on March 20, 2026, Chardan Capital maintained its 'buy' rating, setting a target of $16. Other analysts, including HC Wainwright & Co. and Needham, have also reiterated 'buy' ratings with targets ranging from $11 to $27, reflecting a generally positive outlook.

About ANNX

ANNX is a biopharmaceutical company focused on developing innovative therapies. The company is headquartered in the United States and is dedicated to advancing treatment options for patients through cutting-edge research and development.

Bottom Line

The recent insider buying activity at ANNX, particularly by Ted Yednock, underscores a strong show of confidence from the company's leadership. Institutional investors are also actively engaging with the stock, as seen in the significant changes in holdings. Analysts have set varied price targets, providing a range of expectations for the company's future performance. As always, it's important for investors to consider these developments in the context of their own research and investment strategies.